BACKGROUND: 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) is a novel small-molecule ribonucleotide reductase inhibitor. This study was designed to estimate the maximum tolerated dose (MTD) and oral bioavailability of 3-AP in patients with advanced-stage solid tumors. METHODS: Twenty patients received one dose of intravenous and subsequent cycles of oral 3-AP following a 3 + 3 patient dose escalation. Intravenous 3-AP was administered to every patient at a fixed dose of 100 mg over a 2-h infusion 1 week prior to the first oral cycle. Oral 3-AP was administered every 12 h for 5 consecutive doses on days 1-3, days 8-10, and days 15-17 of every 28-day cycle. 3-AP was started at 50 mg with a planned dose escalation to 100, 150, and 200 mg. Dose-limiting toxicities (DLT) and bioavailability were evaluated. RESULTS: Twenty patients were enrolled. For dose level 1 (50 mg), the second of three treated patients had a DLT of grade 3 hypertension. In the dose level 1 expansion cohort, three patients had no DLTs. No further DLTs were encountered during escalation until the 200-mg dose was reached. At the 200 mg 3-AP dose level, two treated patients had DLTs of grade 3 hypoxia. One additional DLT of grade 4 febrile neutropenia was subsequently observed at the de-escalated 150 mg dose. One DLT in 6 evaluable patients established the MTD as 150 mg per dose on this dosing schedule. Responses in the form of stable disease occurred in 5 (25%) of 20 patients. The oral bioavailability of 3-AP was 67 ± 29% and was consistent with the finding that the MTD by the oral route was 33% higher than by the intravenous route. CONCLUSIONS: Oral 3-AP is well tolerated and has an MTD similar to its intravenous form after accounting for the oral bioavailability. Oral 3-AP is associated with a modest clinical benefit rate of 25% in our treated patient population with advanced solid tumors.
BACKGROUND:3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) is a novel small-molecule ribonucleotide reductase inhibitor. This study was designed to estimate the maximum tolerated dose (MTD) and oral bioavailability of 3-AP in patients with advanced-stage solid tumors. METHODS: Twenty patients received one dose of intravenous and subsequent cycles of oral 3-AP following a 3 + 3 patient dose escalation. Intravenous 3-AP was administered to every patient at a fixed dose of 100 mg over a 2-h infusion 1 week prior to the first oral cycle. Oral 3-AP was administered every 12 h for 5 consecutive doses on days 1-3, days 8-10, and days 15-17 of every 28-day cycle. 3-AP was started at 50 mg with a planned dose escalation to 100, 150, and 200 mg. Dose-limiting toxicities (DLT) and bioavailability were evaluated. RESULTS: Twenty patients were enrolled. For dose level 1 (50 mg), the second of three treated patients had a DLT of grade 3 hypertension. In the dose level 1 expansion cohort, three patients had no DLTs. No further DLTs were encountered during escalation until the 200-mg dose was reached. At the 200 mg 3-AP dose level, two treated patients had DLTs of grade 3 hypoxia. One additional DLT of grade 4 febrile neutropenia was subsequently observed at the de-escalated 150 mg dose. One DLT in 6 evaluable patients established the MTD as 150 mg per dose on this dosing schedule. Responses in the form of stable disease occurred in 5 (25%) of 20 patients. The oral bioavailability of 3-AP was 67 ± 29% and was consistent with the finding that the MTD by the oral route was 33% higher than by the intravenous route. CONCLUSIONS: Oral 3-AP is well tolerated and has an MTD similar to its intravenous form after accounting for the oral bioavailability. Oral 3-AP is associated with a modest clinical benefit rate of 25% in our treated patient population with advanced solid tumors.
Authors: M M Hreshchyshyn; B S Aron; R C Boronow; E W Franklin; H M Shingleton; J A Blessing Journal: Int J Radiat Oncol Biol Phys Date: 1979-03 Impact factor: 7.038
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: O Guittet; P Håkansson; N Voevodskaya; S Fridd; A Gräslund; H Arakawa; Y Nakamura; L Thelander Journal: J Biol Chem Date: 2001-08-21 Impact factor: 5.157
Authors: Charles A Kunos; Tomas Radivoyevitch; John Pink; Song-Mao Chiu; Tammy Stefan; James Jacobberger; Timothy J Kinsella Journal: Radiat Res Date: 2010-09-10 Impact factor: 2.841
Authors: John Murren; Manuel Modiano; Caroline Clairmont; Paula Lambert; Niramol Savaraj; Terry Doyle; Mario Sznol Journal: Clin Cancer Res Date: 2003-09-15 Impact factor: 12.531
Authors: Soumya Poddar; Edmund V Capparelli; Ethan W Rosser; Raymond M Gipson; Liu Wei; Thuc Le; Michael E Jung; Caius Radu; Mina Nikanjam Journal: Biochem Pharmacol Date: 2019-12-06 Impact factor: 5.858
Authors: Anand Joshi; Brian F Kiesel; Nupur Chaphekar; Reyna Jones; Jianxia Guo; Charles A Kunos; Sarah Taylor; Edward Chu; Raman Venkataramanan; Jan H Beumer Journal: Cancer Chemother Pharmacol Date: 2020-09-28 Impact factor: 3.333
Authors: Charles A Kunos; Tomas Radivoyevitch; Steven Waggoner; Robert Debernardo; Kristine Zanotti; Kimberly Resnick; Nancy Fusco; Ramon Adams; Raymond Redline; Peter Faulhaber; Afshin Dowlati Journal: Gynecol Oncol Date: 2013-04-18 Impact factor: 5.482
Authors: Eliška Potůčková; Jaroslav Roh; Miloslav Macháček; Sumit Sahni; Ján Stariat; Vít Šesták; Hana Jansová; Pavlína Hašková; Anna Jirkovská; Kateřina Vávrová; Petra Kovaříková; Danuta S Kalinowski; Des R Richardson; Tomáš Šimůnek Journal: PLoS One Date: 2015-10-13 Impact factor: 3.240
Authors: Henning Karlsson; Mårten Fryknäs; Sara Strese; Joachim Gullbo; Gunnar Westman; Ulf Bremberg; Tobias Sjöblom; Tatjana Pandzic; Rolf Larsson; Peter Nygren Journal: Oncotarget Date: 2017-05-02